This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ciolino, H. P. Articles by Yeh, G. C. Search for Related Content PubMed Articles by Ciolino, H. P. Articles by Yeh, G. C.

Diosmin and Diosmetin Are Agonists of the Aryl Hydrocarbon Receptor That Differentially Affect Cytochrome P450 1A1 Activity

Cellular Defense and Carcinogenesis Section [H. P. C., G. C. Y.], and Laboratory of Nutritional and Molecular Regulation [H. P. C., T. T. Y. W., G. C. Y.], Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, NIH, Frederick, Maryland 21702-1201

We investigated the effect of the chemopreventive compound diosmin and its aglycone form, diosmetin, on the carcinogen activation pathway mediated by the aryl hydrocarbon receptor (AhR) in MCF-7 human breast epithelial cancer cells. Treatment of the cells with diosmin caused a dose-dependent increase in the metabolism of the mammary carcinogen 7,12-dimethylbenz(a)anthracene (DMBA), as assessed by increased formation of DMBA-DNA adducts and by DMBA-induced cytotoxicity. In contrast, treatment of the cells with diosmetin decreased both parameters. Diosmetin, but not diosmin, directly inhibited cytochrome P450 1A1 (CYP1A1) activity in a noncompetitive manner in microsomes isolated from DMBA-treated cells, as assayed by ethyoxyresorufin-O-deethylase activity. Treatment of the cells with diosmin or diosmetin, on the other hand, caused a dose- and time-dependent increase in CYP1A1 activity in intact cells that was comparable to that induced by DMBA or by the aryl hydrocarbon benzo(a)pyrene. Both diosmin and diosmetin caused an increase in the transcription of the CYP1A1 gene, as measured by increased levels of CYP1A1 mRNA. Both compounds caused the activation of the DNA-binding capacity of the AhR for the xenobiotic-responsive element of CYP1A1. These results indicate that diosmin and diosmetin are natural dietary agonists of the AhR, causing a potent increase in CYP1A1 transcription and CYP1A1 activity; however, only diosmetin is capable of inhibiting CYP1A1 enzyme activity, thus inhibiting carcinogen activation.

¹ To whom requests for reprints should be addressed, at Laboratory of Nutritional and Molecular Regulation, National Cancer Institute-Frederick Cancer Research and Development Center, Building 560/Room 12-05, P. O. Box B, Frederick, MD 21702-1201. Phone: (301) 846-5160; Fax: (301) 846-6093; E-mail: hciolino@mail.ncifcrf.gov.

Received 1/13/98. Accepted 4/30/98.

This article has been cited by other articles:

				P. Sienkiewicz, H. P. Ciolino, B. J. Leslie, P. J. Hergenrother, K. Singletary, and G. C. Yeh A novel synthetic analogue of a constituent of Isodon excisus inhibits transcription of CYP1A1, -1A2 and -1B1 by preventing activation of the aryl hydrocarbon receptor Carcinogenesis, May 1, 2007; 28(5): 1052 - 1057. [Abstract] [Full Text] [PDF]

				S.-H. Kim, E. C. Henry, D.-K. Kim, Y.-H. Kim, K. J. Shin, M. S. Han, T. G. Lee, J.-K. Kang, T. A. Gasiewicz, S. H. Ryu, et al. Novel Compound 2-Methyl-2H-pyrazole-3-carboxylic Acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) Prevents 2,3,7,8-TCDD-Induced Toxicity by Antagonizing the Aryl Hydrocarbon Receptor Mol. Pharmacol., June 1, 2006; 69(6): 1871 - 1878. [Abstract] [Full Text] [PDF]

				S. Mulero-Navarro, E. Pozo-Guisado, P. A. Perez-Mancera, A. Alvarez-Barrientos, I. Catalina-Fernandez, E. Hernandez-Nieto, J. Saenz-Santamaria, N. Martinez, J. M. Rojas, I. Sanchez-Garcia, et al. Immortalized Mouse Mammary Fibroblasts Lacking Dioxin Receptor Have Impaired Tumorigenicity in a Subcutaneous Mouse Xenograft Model J. Biol. Chem., August 5, 2005; 280(31): 28731 - 28741. [Abstract] [Full Text] [PDF]

				R. Torkin, J.-F. Lavoie, D. R. Kaplan, and H. Yeger Induction of caspase-dependent, p53-mediated apoptosis by apigenin in human neuroblastoma Mol. Cancer Ther., January 1, 2005; 4(1): 1 - 11. [Abstract] [Full Text] [PDF]

				D. Nikolic and R. B. van Breemen NEW METABOLIC PATHWAYS FOR FLAVANONES CATALYZED BY RAT LIVER MICROSOMES Drug Metab. Dispos., April 1, 2004; 32(4): 387 - 397. [Abstract] [Full Text] [PDF]

				C. J. MacDonald, H. P. Ciolino, and G. C. Yeh The Drug Salicylamide Is an Antagonist of the Aryl Hydrocarbon Receptor That Inhibits Signal Transduction Induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin Cancer Res., January 1, 2004; 64(1): 429 - 434. [Abstract] [Full Text] [PDF]

				C. J. Gambone, J. M. Hutcheson, J. L. Gabriel, R. L. Beard, R. A.S. Chandraratna, K. J. Soprano, and D. R. Soprano Unique Property of Some Synthetic Retinoids: Activation of the Aryl Hydrocarbon Receptor Pathway Mol. Pharmacol., February 1, 2002; 61(2): 334 - 342. [Abstract] [Full Text] [PDF]

				M. D. Roth, J. A. Marques-Magallanes, M. Yuan, W. Sun, D. P. Tashkin, and O. Hankinson Induction and Regulation of the Carcinogen-Metabolizing Enzyme CYP1A1 by Marijuana Smoke and Delta 9-Tetrahydrocannabinol Am. J. Respir. Cell Mol. Biol., March 1, 2001; 24(3): 339 - 344. [Abstract] [Full Text] [PDF]

				J.-E. Lee and S. Safe 3',4'-Dimethoxyflavone as an Aryl Hydrocarbon Receptor Antagonist in Human Breast Cancer Cells Toxicol. Sci., December 1, 2000; 58(2): 235 - 242. [Abstract] [Full Text] [PDF]

				H. P. Ciolino and G. C. Yeh The Steroid Hormone Dehydroepiandrosterone Inhibits CYP1A1 Expression in Vitro By a Post-transcriptional Mechanism J. Biol. Chem., December 3, 1999; 274(49): 35186 - 35190. [Abstract] [Full Text] [PDF]

				E. C. Henry, A. S. Kende, G. Rucci, M. J. Totleben, J. J. Willey, S. D. Dertinger, R. S. Pollenz, J. P. Jones, and T. A. Gasiewicz Flavone Antagonists Bind Competitively with 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) to the Aryl Hydrocarbon Receptor But Inhibit Nuclear Uptake and Transformation Mol. Pharmacol., April 1, 1999; 55(4): 716 - 725. [Abstract] [Full Text]

				F. J. Gonzalez and P. Fernandez-Salguero The Aryl Hydrocarbon Receptor. Studies Using the AHR-Null Mice Drug Metab. Dispos., December 1, 1998; 26(12): 1194 - 1198. [Abstract] [Full Text]